Y-Mabs Therapeutics Profit Margin

As of the most recent data (June 2025), YMAB shows a profit margin of -26.03%. That compares with -28.44% in the prior-year period — up 8.5% year over year. That is below the Healthcare sector average of 13.76%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, YMAB's profit margin is now -26.03% (was -28.44%) — a 8.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Y-Mabs Therapeutics is outperforming or lagging.

The Healthcare sector average profit margin is about 13.76%. Y-Mabs Therapeutics is at -26.03%, which is lower that average. That is roughly 289.1% below the sector mean. Use the comparison chart on this page to see how YMAB stacks up against individual peers as well.

That compares with -28.44% in the prior-year period — up 8.5% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Y-Mabs Therapeutics with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has Y-Mabs Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently -26.03%) with ownership activity and broader fundamentals.